Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTAIN
2023-503645-63-00Phase 3Authorised
- Sponsor
- CHU de Nantes
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amoxicillin and amoxicillin + clavulanate in community-acquired pneumonia (CAP) (2 arms), sponsored by CHU de Nantes. Primary endpoint: Clinical success rate at Day 30. Planned start Jan 2024; status: authorised.
02
Drugs
amoxicillinamoxicillin + clavulanate
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2023-503645-63-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503645-63-00.